

## Switzerland

### Recent and planned developments in pharmaceutical policies 2014

#### Policies related to high cost medicines

<b>D E V E L O P M E N T S</b>	<b>Changes in pricing</b>	<b>Changes in reimbursement</b>
	<ul style="list-style-type: none"> <li>• <u>Revision of the health insurance law until 1.6. 2015:</u></li> <li>• More transparency in processes for SL-admission (positive list).</li> <li>• Benefit assessment.</li> <li>• <u>EPR/ IPR (daily costs/ cost per cure):</u> External price referencing will be considered stronger than internal price referencing (daily costs/ cost per cure): EPR:IPR = 2:1.</li> </ul> <p>Prices higher (at most 5% higher than the European average) than the European average price will be accepted.</p> <ul style="list-style-type: none"> <li>• <u>Changes in the country basket in EPR:</u> From 2015 onwards, Belgium, Finland and Sweden will be added to Austria, Denmark, the Netherlands, France, Germany and UK.</li> </ul>	<p>There are no changes planned in reimbursement.</p>
<b>Other changes 2015</b>		
<ul style="list-style-type: none"> <li>• The impact of a reference pricing system for biosimilars and generics will be analysed.</li> </ul>		
<b>S P E C I A L T O P I C</b>	<b>High cost medicines</b>	
	<ul style="list-style-type: none"> <li>• <u>Special pricing policies:</u> There are no specific pricing policies for high cost medicines.</li> <li>• <u>Special reimbursement/funding policies:</u> The reimbursement of SL products may be restricted to certain medical indications or specified quantities (so-called limitations). Sovaldi for instance, is reimbursed for patients with advanced fibrosis (Metavir score F3 to F4, Fibroscan &gt; 9.5kPa) or for patients with extrahepatic manifestations.</li> <li>• <u>High cost medicines at the interface of out-patient and in-patient sectors:</u> The costs for an in-patient hospital stay are billed according to DRG fees. For few high-cost medicines additional fees can be allocated.</li> </ul> <p><u>Key challenges and solutions:</u></p> <ol style="list-style-type: none"> <li>1. New high cost medicines</li> <li>2. Medicines at the interface of the out-patient and in-patient sectors. Solutions: no specific measures are planned.</li> </ol>	